MAP1A and non-small cell lung carcinoma: According to Luo (40), the expression of MAP1A was closely correlated with the immunotherapeutic response of non-small cell lung cancer, and MAP1A is expected to serve as an immunotherapeutic target for non-small cell lung cancer (NSCLC).